一名接受硼替佐米治疗的华氏巨球蛋白血症患者出现听力损失
Hearing Loss in a Patient with Waldenstrom Macroglobulinemia Receiving Bortezomib.
作者信息
Fitzsimons Jack, Phelan Kathleen, Dhanarajan Asha
机构信息
Department of Medicine, Loyola University Medical Center, Maywood, IL, USA.
Division of Hematology and Oncology, Hines Veterans Affairs Hospital, Hines, IL, USA.
出版信息
Case Rep Oncol. 2024 Jun 18;17(1):653-657. doi: 10.1159/000539453. eCollection 2024 Jan-Dec.
Abstract
INTRODUCTION
We present a case report of hearing loss in a patient with Waldenstrom macroglobulinemia (WM) receiving treatment with bortezomib.
CASE PRESENTATION
Our patient developed sudden bilateral sensorineural hearing loss after receiving three doses of bortezomib. His hearing loss was irreversible and resulted in a cochlear implant.
CONCLUSION
Hearing loss secondary to bortezomib is a known, but very rare, side effect. Hearing loss secondary to WM is also rare and has been described in case reports.
摘要
引言
我们报告一例接受硼替佐米治疗的华氏巨球蛋白血症（WM）患者出现听力丧失的病例。
病例介绍
我们的患者在接受三剂硼替佐米治疗后出现双侧突发性感音神经性听力丧失。他的听力丧失是不可逆的，最终接受了人工耳蜗植入。
结论
硼替佐米引起的听力丧失是一种已知但非常罕见的副作用。WM引起的听力丧失也很罕见，已有病例报告对此进行过描述。
相似文献
1
Hearing Loss in a Patient with Waldenstrom Macroglobulinemia Receiving Bortezomib.一名接受硼替佐米治疗的华氏巨球蛋白血症患者出现听力损失
Case Rep Oncol. 2024 Jun 18;17(1):653-657. doi: 10.1159/000539453. eCollection 2024 Jan-Dec.
2
Bilateral central retinal vein occlusion as an initial presentation of Waldenström macroglobulinemia: a case report.双侧中央视网膜静脉阻塞作为华氏巨球蛋白血症的首发表现：一例报告。
J Med Case Rep. 2023 Feb 20;17(1):59. doi: 10.1186/s13256-023-03778-4.
3
Simultaneous presentation of Waldenström macroglobulinemia and multiple myeloma: multidisciplinary diagnosis, treatment and 30-month follow-up.华氏巨球蛋白血症与多发性骨髓瘤同时出现：多学科诊断、治疗及30个月随访
J Clin Exp Hematop. 2013;53(1):29-36. doi: 10.3960/jslrt.53.29.
4
Bortezomib-based chemotherapy for patients with Waldenström macroglobulinemia: a single-center experience.硼替佐米为基础的化疗治疗华氏巨球蛋白血症患者：单中心经验。
Ann Hematol. 2023 Jan;102(1):167-174. doi: 10.1007/s00277-022-05019-y. Epub 2022 Nov 14.
5
Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia.新型肿瘤靶向脂质体由 MDM2 拮抗剂和蛋白酶体抑制剂组成，在硼替佐米耐药华氏巨球蛋白血症的异种移植模型中显示出抗肿瘤活性。
Leuk Lymphoma. 2020 Oct;61(10):2399-2408. doi: 10.1080/10428194.2020.1775204. Epub 2020 Jun 19.
6
Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports.免疫球蛋白 M（IgM）多发性骨髓瘤与华氏巨球蛋白血症：诊断挑战与治疗选择：两例报告。
J Med Case Rep. 2020 Jun 22;14(1):75. doi: 10.1186/s13256-020-02380-2.
7
Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.硼替佐米作为华氏巨球蛋白血症患者的治疗选择。
Clin Lymphoma Myeloma Leuk. 2010 Apr;10(2):110-7. doi: 10.3816/CLML.2010.n.015.
8
When Waldenström macroglobulinemia hits the kidney: Description of a case series and management of a "rare in rare" scenario.当华氏巨球蛋白血症累及肾脏时：病例系列描述及“罕见中的罕见”情况的处理
Cancer Rep (Hoboken). 2024 Apr;7(4):e2062. doi: 10.1002/cnr2.2062.
9
Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia.TORC1 抑制剂依维莫司在华氏巨球蛋白血症中的作用机制。
Clin Cancer Res. 2012 Dec 15;18(24):6609-22. doi: 10.1158/1078-0432.CCR-12-1532. Epub 2012 Oct 9.
10
Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.家族性疾病易感性对瓦尔登斯特伦巨球蛋白血症患者的治疗结果有影响。
Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):433-7. doi: 10.1016/j.clml.2012.08.006. Epub 2012 Oct 17.
本文引用的文献
1
Relation between auditory difficulties and bortezomib-induced peripheral neuropathy in multiple myeloma: a single-center cross-sectional study.多发性骨髓瘤患者听觉障碍与硼替佐米诱导的周围神经病变之间的关系：一项单中心横断面研究
Eur Arch Otorhinolaryngol. 2022 Apr;279(4):2197-2201. doi: 10.1007/s00405-021-07234-1. Epub 2022 Jan 31.
2
Sensorineural deafness: An uncommon irreversible adverse effect of bortezomib.感音神经性耳聋：硼替佐米一种罕见的不可逆不良反应。
Indian J Cancer. 2016 Jul-Sep;53(3):459. doi: 10.4103/0019-509X.200675.
3
Bilateral Sudden Hearing Loss in Waldenstrom's Macroglobulinemia: MR Appearance.华氏巨球蛋白血症中的双侧突发性听力损失：磁共振成像表现
Radiol Case Rep. 2015 Nov 6;1(3):77-9. doi: 10.2484/rcr.v1i3.25. eCollection 2006.
4
Proteasome inhibitors induce auditory hair cell death through peroxisome dysfunction.蛋白酶体抑制剂通过过氧化物酶体功能障碍诱导听觉毛细胞死亡。
Biochem Biophys Res Commun. 2015 Jan 2;456(1):269-74. doi: 10.1016/j.bbrc.2014.11.070. Epub 2014 Nov 25.
5
Deafness associated with the use of Bortezomib in multiple myeloma.与硼替佐米用于多发性骨髓瘤相关的耳聋。
Acta Oncol. 2008;47(2):323-4. doi: 10.1080/02841860701558823.
6
Severe irreversible bilateral hearing loss after bortezomib (VELCADE) therapy in a multiple myeloma (MM) patient.
Leukemia. 2005 May;19(5):869-70. doi: 10.1038/sj.leu.2403723.
7
Waldenstrom's macroglobulinemia and sensorineural hearing loss.华氏巨球蛋白血症与感音神经性听力损失
Am J Otolaryngol. 2001 Sep-Oct;22(5):349-53. doi: 10.1053/ajot.2001.26494.
8
Deafness due to Waldenstrom macroglobulinaemia.
J Laryngol Otol. 1971 Mar;85(3):275-80. doi: 10.1017/s0022215100073424.
9
Otolaryngological disturbances in Waldenstrom's macroglobulinaemia.华氏巨球蛋白血症的耳鼻喉科紊乱
Clin Otolaryngol Allied Sci. 1977 Nov;2(4):327-38. doi: 10.1111/j.1365-2273.1977.tb01376.x.
10
Deafness and Waldenström's macroglobulinemia.
South Med J. 1979 Nov;72(11):1495-6. doi: 10.1097/00007611-197911000-00051.
Zotero 插件